340B Rebate Model Delay Act
- Sponsor
- Rep. Bresnahan, Robert P. [R-PA-8]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Oct 9, 2026
Bottom line
This bill aims to maintain the current 340B drug pricing structure by delaying the implementation of a new rebate model and ensuring point-of-purchase discounts for eligible healthcare providers for a two-year period.
What it actually does
This bill temporarily prohibits the Secretary of Health and Human Services from implementing a 340B Rebate Model Pilot Program or any substantially similar initiative for two years, from January 1, 2027, to December 31, 2028. During this period, it also prevents the Secretary from entering into agreements with drug manufacturers that would allow most covered entities to pay more than the applicable ceiling price for covered outpatient drugs at the point of purchase, effectively pausing a shift towards a rebate-based model and maintaining upfront discounts.
Proponents argue
Supporters argue this delay is crucial to prevent disruption to the 340B program, which provides significant discounts on outpatient drugs to eligible healthcare providers, allowing them to stretch scarce federal resources. They contend that a new rebate model could complicate drug acquisition, reduce the immediate financial benefit to covered entities, and potentially jeopardize patient access to affordable medications, especially for vulnerable populations served by these entities. The delay provides time for further study and stakeholder input.
Opponents contend
Opponents, if any, might argue that delaying the rebate model perpetuates inefficiencies or unintended consequences within the existing 340B program. They might suggest that a rebate model could offer greater transparency, better align incentives, or address concerns about how 340B savings are utilized by covered entities. Some might also argue that the current system allows certain entities to profit excessively without directly passing savings to patients, and a new model could address this.
The bill text is very short and can be read quickly, making it accessible for immediate understanding of its core action.
Section 2(a) and 2(b)
Temporary Limit on 340B Rebates and Delay of Pilot Program
This provision establishes a two-year moratorium, from January 1, 2027, to December 31, 2028, on changes to how certain 340B drug discounts are handled. Specifically, it prevents the Department of Health and Human Services (HHS) from implementing a new '340B Rebate Model Pilot Program' that was previously announced. Concurrently, it ensures that for most eligible healthcare providers participating in the 340B program, drug manufacturers cannot charge more than the established 'ceiling price' for covered outpatient drugs at the time of purchase, effectively maintaining the current upfront discount system rather than shifting to a rebate system during this period.
Supporters argue
Supporters argue that maintaining the point-of-purchase discount is critical for the financial stability of 340B entities, many of which serve low-income and rural populations. They contend that a shift to a rebate model could create cash flow problems, increase administrative complexity, and reduce the immediate benefit of the program, potentially forcing entities to cut services or limit access to care. The delay provides a necessary pause to assess the implications of such a significant change.
Critics contend
Critics, particularly some drug manufacturers or those advocating for 340B reform, might argue that delaying the rebate model prevents necessary modernization and transparency in the program. They might assert that the current point-of-purchase discount system lacks sufficient oversight regarding how savings are used, and a rebate model could allow for better tracking and ensure savings are passed on to patients or reinvested appropriately. They may also argue that the current system leads to inflated drug prices for non-340B purchasers.
Tradeoffs
The provision balances the desire for program stability and immediate financial benefit for covered entities against potential calls for greater transparency, oversight, or reform of the 340B program's financial mechanisms. It temporarily resolves the tension by favoring the status quo of upfront discounts over a new rebate model.